نتایج جستجو برای: ipilimumab
تعداد نتایج: 1961 فیلتر نتایج به سال:
AIM To investigate management of patients who develop ipilimumab-mediated enterocolitis, including association of endoscopic findings with steroid-refractory symptoms and utility of infliximab as second-line therapy. METHODS We retrospectively reviewed all patients at our center with metastatic melanoma who were treated with ipilimumab between March 2011 and May 2014. All patients received a ...
OBJECTIVES Our aim was to evaluate the safety and efficacy of ipilimumab combined with standard first-line chemotherapy for patients with extensive-stage SCLC. METHODS Patients with chemotherapy-naive extensive-stage SCLC were treated with carboplatin and etoposide for up to six cycles. Ipilimumab, 10 mg/kg, was given on day 1 of cycles 3 to 6 and every 12 weeks. Response was assessed by the ...
BACKGROUND Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor cells. Ipilimumab is a monoclonal antibody directed against CTLA-4. OBJECTIVE This review describes the basic mechanism of ipilimumab and discusses data available to date with regards to its safety and efficacy profile. METHODS Data from clinical trials including abstr...
BACKGROUND Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused. CASE PRESENTATION A 42 year old male with Stage IV metastatic melanoma developed lower extremity weakness and sensory neuropathy following three doses of Ipilimumab. MRI of...
Treatment for advanced prostate cancer has and will continue to grow increasingly complex, owing to the introduction of multiple new therapeutic approaches with the potential to substantially improve outcomes for this disease. Agents that modulate the patient's immune system to fight prostate cancer - immunotherapeutics - are among the most exciting of these new approaches. The addition of anti...
Immune checkpoint therapies, such as ipilimumab, induce dramatic antitumor responses in a subset of patients with advanced malignancies, but they may also induce inflammatory responses and toxicities termed immune-related adverse events (irAEs). These irAEs are often low grade and manageable, but severe irAEs may lead to prolonged hospitalizations or fatalities. Early intervention is necessary ...
There is a paucity of population-based data regarding ipilimumab-induced gastrointestinal and hepatic immune-related adverse events (irAE) during cutaneous melanoma treatment. We examined the risk predictors irAE in national cohort patients diagnosed with melanoma. This retrospective study used Surveillance, Epidemiology End Results - Medicare linked between years 2010 2015 treated ipilimumab o...
introduction: the incidence of malignant melanoma is increasing at a rate greater than any other human cancer. although melanoma accounts for only 4 percent of all dermatologic cancers, it is responsible for 80 percent of deaths from skin cancer; only 14 percent of patients with metastatic melanoma survive for five years. the optimal therapy varies with the stage of the disease. surgical excisi...
While human immunity is generally thought to protect against infectious agents, there is also evidence for immune surveillance against neoplastic diseases. Some malignant cells are able to evade or down-regulate this immune response through a variety of chemical mediators, rendering the host response ineffective and leading to poor prognoses. Immune mechanisms seem particularly important in the...
BACKGROUND Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. H...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید